New Codes for Pfizer and Moderna Bivalent COVID-19 Vaccines, CR 118032
On April 18, 2023, the Food and Drug Administration (FDA) announced changes to simplify the use of Bivalent mRNA COVID-19 vaccines. As a result, additional CPT codes have been created by the American Medical Association (AMA) for use in billing for the administration of COVID-19 vaccines. The chart below indicates the CPT codes assigned to the vaccine and the new administration codes associated with them.
Moderna Bivalent COVID-19 Vaccine -12 years and older |
|||
Code |
Description |
Effective Date |
MaineCare Rate |
91313 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use |
08/31/22 |
$0* |
0134A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, additional dose |
08/31/22 |
$39.11 |
Moderna Bivalent COVID-19 Vaccine -6-11 years old |
|||
Code |
Description |
Effective Date |
MaineCare Rate |
91314 |
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use |
10/12/22 |
$0* |
0141A** |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease COVID-19) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use; 1st dose |
04/18/23 |
$39.11 |
0142A** |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease COVID-19) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use; 2nd dose |
04/18/23 |
$39.11 |
0144A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNLNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, additional dose |
10/12/22 |
$39.11 |
Moderna Bivalent COVID-19 Vaccine -6 months to 5 years old |
|||
Code |
Description |
Effective Date |
MaineCare Rate |
91316 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use |
12/08/22 |
$0* |
0164A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose |
12/08/22 |
$39.11 |
Pfizer BioN-Tech Bivalent COVID-19 Vaccine -12 years and older |
|||
Code |
Description |
Effective Date |
MaineCare Rate |
91312 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
08/31/22 |
$0* |
0121A** |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use; 1st Dose |
04/18/23 |
$39.11 |
0124A |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use; additional dose |
08/31/22 |
$39.11 |
Pfizer BioN-Tech Bivalent COVID-19 Vaccine – 5-11 years old |
|||
Code |
Description |
Effective Date |
MaineCare Rate |
91315 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use |
10/12/22 |
$0* |
0151A** |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use;1st dose |
04/18/23 |
$39.11 |
0154A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, additional dose |
10/12/22 |
$39.11 |
Pfizer BioN-Tech Bivalent COVID-19 Vaccine – 6 months to 4 years old |
|||
Code |
Description |
Effective Date |
MaineCare Rate |
91317 |
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use |
12/08/22 |
$0 |
0171A** |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use; 1st dose |
04/18/23 |
$39.11 |
0172A** |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use; 2nd dose |
04/18/23 |
$39.11 |
0173A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose |
12/08/22 |
$39.11 |
0174A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, additional dose |
03/14/23 |
$39.11 |
*Government Supplied Vaccines **New CPT code for Bivalent COVID-19 vaccine administration Note: The COVID-19 vaccine administration codes will be added for roster billing |
Providers may visit the Maine CDC Immunization Program Website for up-to-date information on administering and ordering COVID-19 vaccines.
If you have questions about the use of Bivalent COVID-19 vaccine booster doses, please contact your Provider Relations Specialist.
Check out our new MaineCare logo! Learn more about this logo on the About Us page of our website.